CYP26A1 and keratinization disease: In this study, we establish a preclinical assessment of the pharmacological and toxicological properties of recently discovered dual CYP26A1/B1‐selective inhibitor, DX308, as a potential topical treatment for keratinization disorders and other retinoid‐responsive dermatological disorders.